Immunomic Therapeutics has commenced its Phase I clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer. ITI-1001 is an investigational plasmid DNA vaccine therapy designed to target the pp65, IE-1 and gB viral antigens of Cytomegalovirus (CMV) which are expressed […]